Halozyme Therapeutics, Inc.
HALONASDAQHealthcare● Active
$71.53
$-0.07(-0.10%)
Market Cap$8.5B
P/E Ratio—
52W High$82.22
52W Low$51.06
Halozyme Therapeutics, Inc. (HALO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HALO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.40B | $1.02B | $0.83B | $0.66B | $0.44B |
| Cost of Revenue | $0.31B | $0.16B | $0.19B | $0.14B | $0.08B |
| Gross Profit | $1.09B | $0.86B | $0.64B | $0.52B | $0.36B |
| Gross Margin %(computed) | 78.13% | 84.30% | 76.80% | 78.90% | 81.64% |
| Operating Expenses | |||||
| R&D Expenses | $0.08B | $0.08B | $0.08B | $0.07B | $0.04B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.27B | $0.30B | $0.30B | $0.25B | $0.09B |
| Operating Income | $0.82B | $0.55B | $0.34B | $0.27B | $0.28B |
| Operating Margin %(computed) | 58.45% | 54.32% | 40.71% | 40.53% | 62.24% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.02B | $0.02B | $0.02B | $0.02B | $0.01B |
| Income Before Tax | $0.47B | $0.56B | $0.35B | $0.25B | $0.25B |
| Income Tax Expense | $0.15B | $0.11B | $0.07B | $0.05B | ($0.15B) |
| Net Income | $0.32B | $0.44B | $0.28B | $0.20B | $0.40B |
| Net Margin %(computed) | 22.69% | 43.74% | 33.96% | 30.62% | 90.84% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.64 | $3.50 | $2.13 | $1.48 | $2.86 |
| Wtd Avg Shares | 0.12B | 0.13B | 0.13B | 0.14B | 0.14B |
| EBITDA | $0.90B | $0.66B | $0.45B | $0.32B | $0.26B |
| EBITDA Margin %(computed) | 64.75% | 64.66% | 54.50% | 47.80% | 58.43% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Halozyme Therapeutics, Inc. data
About Halozyme Therapeutics, Inc. (HALO) Income Statement
Halozyme Therapeutics, Inc. (HALO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, HALO reported revenue of $1.40B, gross profit of $1.09B (gross margin 78.13%), and net income of $0.32B — a net profit margin of 22.69%.
Frequently asked questions
HALO · 4 questionsHalozyme Therapeutics, Inc. (HALO) reported revenue of $1.40B for 2025, up 37.6% year-over-year.
HALO revenueHALO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08